Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Net Cash Flow (2019 - 2025)

Pulmonx (LUNG) has disclosed Net Cash Flow for 7 consecutive years, with $722000.0 as the latest value for Q3 2025.

  • Quarterly Net Cash Flow rose 7120.0% to $722000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Sep 2025, up 142.85% year-over-year, with the annual reading at -$12.7 million for FY2024, 30.5% up from the prior year.
  • Net Cash Flow for Q3 2025 was $722000.0 at Pulmonx, down from $1.5 million in the prior quarter.
  • The five-year high for Net Cash Flow was $8.6 million in Q1 2023, with the low at -$39.7 million in Q4 2021.
  • Average Net Cash Flow over 5 years is -$8.2 million, with a median of -$8.6 million recorded in 2023.
  • The sharpest move saw Net Cash Flow crashed 1596.29% in 2021, then surged 7120.0% in 2025.
  • Over 5 years, Net Cash Flow stood at -$39.7 million in 2021, then surged by 73.69% to -$10.4 million in 2022, then fell by 7.12% to -$11.2 million in 2023, then skyrocketed by 166.41% to $7.4 million in 2024, then crashed by 90.28% to $722000.0 in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $722000.0, $1.5 million, and $3.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.